Genmab reports 28.2‑month median overall survival for petosemtamab + pembrolizumab in Phase 2 head‑and‑neck cancer
Genmab announced updated Phase 2 results for petosemtamab combined with pembrolizumab in first‑line PD‑L1‑positive recurrent or metastatic head‑and‑neck squamous cell carcinoma. The regimen achieved a median overall survival of 28.2 months, a 63% objective response rate and a median progression‑free survival of 9.0 months among 43 efficacy‑evaluable patients. The data were presented at the ESMO Congress 2026 and support the ongoing Phase 3 LiGeR‑HN1 trial slated for topline results later in 2026.
Why it matters
Genmab’s stock rose about 9.5% on October 23 2026 after the release, reflecting investor optimism that the strong Phase 2 outcomes could translate into a positive Phase 3 read‑out. The results also raise expectations for future revenue growth if the combination receives regulatory approval for head‑and‑neck cancer.
Key facts
- 1Median overall survival was 28.2 months. grafa.com
- 2Objective response rate was 63%. rttnews.com
- 3Median progression‑free survival was 9.0 months. marketscreener.com
- 4Complete response rate was 19%. grafa.com
- 5Median follow‑up at data cutoff (May 15 2026) was 25.5 months. rttnews.com
- 612‑month overall survival rate was 79%. grafa.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.